Back to top
more

Fate Therapeutics (FATE)

(Delayed Data from NSDQ)

$2.42 USD

2.42
1,957,758

-0.13 (-5.10%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $2.42 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

by Zacks Equity Research

Fate Therapeutics (FATE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Fate Therapeutics (FATE) Down 8.9% Since Last Earnings Report?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues for the fourth quarter.

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 32.56% and 124.91%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q4 Earnings on Feb 28: NVAX, IOVA & More

by Kinjel Shah

Let us look at four drug and biotech companies, NVAX, IOVA, ALLO, SRPT and FATE, which are gearing up for their earnings release.

Wall Street Analysts Believe Fate Therapeutics (FATE) Could Rally 172.49%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at a 172.5% upside potential for Fate Therapeutics (FATE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Down -52.57% in 4 Weeks, Here's Why Fate Therapeutics (FATE) Looks Ripe for a Turnaround

by Zacks Equity Research

Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

FATE To End Janssen Deal and Prioritize Pipeline Development

by Zacks Equity Research

FATE decides not to continue its collaboration and option agreement with Janssen. The company also conducts a strategic review.

Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?

by Zacks Equity Research

Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Fate Therapeutics (FATE) Loses -50.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Fate Therapeutics (FATE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 7.53% and 2.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Emergent Biosolutions (EBS) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Fate Therapeutics (FATE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Fate Therapeutics (FATE) Down 17% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fate Therapeutics (FATE) delivered earnings and revenue surprises of 8.14% and 38.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XBI

Acadia (ACAD) Files an NDA for Its Rett Syndrome Candidate

by Zacks Equity Research

Acadia (ACAD) submits a new drug application to the FDA for trofinetide to treat Rett syndrome in patients aged two and older.

Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

by Zacks Equity Research

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome

by Zacks Equity Research

The FDA bestows an Orphan Drug designation to Amryt's (AMYT) Mycapssa for the treatment of carcinoid syndrome. Stock up in pre-market trading.

Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA

by Zacks Equity Research

The FDA's potential approval of Perrigo (PRGO) unit, HRA Pharma's OTC birth control pills can make the drug the first of its kind to be made available without prescription in the United States.